🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

    Sanofi-aventis Healthcare Pty Ltd

    Kidney transplant rejection

    phase 3 small molecule active

    1 trial

  2. Prolia 60 mg solution for injection in pre-filled syringe, LY06006

    Wuhan Createrna Science and Technology Co., Ltd

    Postmenopausal osteoporosis

    phase 3 small molecule active

    1 trial

  3. QVA149

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  4. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect

    Advanced Accelerator Applications

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. REGN1908

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule completed

    1 trial

  7. REGN5713

    Regeneron UK Limited

    Allergic Conjunctivitis

    phase 3 small molecule active

    2 trials

  8. RESPIRATORY SYNCYTIAL VIRUS VACCINES

    The George Institute

    RSV infection

    phase 3 small molecule active

    1 trial

  9. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  10. RHB-105

    RedHill Biopharma

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  11. RHB-204

    RedHill Biopharma

    Pulmonary Mycobacterium Avium Complex Infection

    phase 3 small molecule terminated

    1 trial

  12. RIFADINE 300 mg, gélule, ANSATIPINE 150 mg, gélule

    Tour Hekla

    Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)

    phase 3 small molecule active

    1 trial

  13. RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE

    Takeda

    Active Chronic Pouchitis

    phase 3 small molecule active

    1 trial

  14. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  15. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  16. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe, RO4893594

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  17. RO4893594, RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  18. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  19. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  20. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  21. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  22. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  23. RSV MAT

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 mab terminated

    1 trial

  24. RSVpreF

    Pfizer

    Respiratory Tract Infection

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources